Company / Operating Margin
Travere Therapeutics, Inc. Operating Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
-12.8%
FY2025
5-year range
-292.2% / -12.8%
FY2021-FY2025
Trend
+90.8%
vs FY2024
Sector context
#63 of 136
Health Care
What the data says
At -12.8%, Travere Therapeutics, Inc.'s operating margin ranks #63 of 136 in the Health Care sector. Operating Margin has increased for 3 consecutive years, from -292.2% in FY2022 to -12.8% in FY2025.
Based on SEC 10-K filings.
-12.8% in FY2025 with a 5-year CAGR of +35.9%.
Improved from -267.2% to -12.8% over the past 2 years.
Health Care sector context is included.
Operating Margin over time
Growth rates
- 3-Year Change
- +279.4pp
- 5-Year Change
- +35.9pp
- 10-Year Change
- -
Sector benchmark
#63 of 136 in Health CareTop 46% of 136This company -12.8% Sector average -778.9%
▼
+98.4% above sector average
Key checks
Key Insights
- Travere Therapeutics, Inc.'s operating margin has grown for 3 consecutive years.
- In FY2025, operating margin increased 90.8% year-over-year.
- Currently 766.1pp above the Health Care sector average.
- Lowest operating margin in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -12.8% | +90.8% |
| FY2024 | -138.9% | +48.0% |
| FY2023 | -267.2% | +8.5% |
| FY2022 | -292.2% | -273.0% |
| FY2021 | -78.3% | -60.8% |
| FY2020 | -48.7% | -40.4% |
| FY2019 | -34.7% | +20.3% |
| FY2018 | -43.6% | +14.2% |
| FY2017 | -50.8% | +82.0% |
| FY2016 | -283.0% | -457.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026